Patents by Inventor Tatiana Sirakova
Tatiana Sirakova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8551499Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.Type: GrantFiled: August 13, 2012Date of Patent: October 8, 2013Assignee: University of Central Florida Research Foundation, Inc.Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajyoti Deb
-
Publication number: 20130040829Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.Type: ApplicationFiled: August 13, 2012Publication date: February 14, 2013Applicant: University of Central Florida Research Foundation, Inc.Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajoti Deb
-
Patent number: 8241644Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.Type: GrantFiled: August 30, 2010Date of Patent: August 14, 2012Assignee: University of Central Florida Research Foundation, Inc.Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajyoti Deb
-
Patent number: 8211446Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.Type: GrantFiled: August 30, 2010Date of Patent: July 3, 2012Assignee: University of Central Florida Research Foundation, Inc.Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajyoti Deb
-
Patent number: 8012492Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.Type: GrantFiled: April 22, 2008Date of Patent: September 6, 2011Assignee: University of Central Florida Research Foundation, Inc.Inventors: Pappachan Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajyoti Deb
-
Patent number: 7993658Abstract: Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the implementation or manipulation of triacylglycerol synthase like polypeptides or polynucleotides encoding the same. The methods are useful in identifying agents active against TB infection.Type: GrantFiled: August 24, 2009Date of Patent: August 9, 2011Assignee: University of Central Florida Research Foundation, Inc.Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Vinod S. Dubey, Jaiyanth Daniel
-
Publication number: 20110190479Abstract: The application reports the discovery that mycobacterial triacylglycerol synthase (MTTGS) enzymes also have a wax synthase function. This bifunctional enzymatic activity, or ‘dual function,’ implies that the enzymes contain separate binding sites for diacylglycerol and acyl alcohol and a common binding site for acyl-coenzyme A. Embodiments of the invention relate to methods of selection and/or design of therapeutic compounds that will reduce any potentially toxic side effects of candidate drugs designed to inhibit the mycobacterial enzyme.Type: ApplicationFiled: January 3, 2011Publication date: August 4, 2011Inventors: PAPPACHAN E. KOLATTUKUDY, TATIANA SIRAKOVA, VINOD S. DUBEY, JAIYANTH DANIEL
-
Publication number: 20110033915Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.Type: ApplicationFiled: August 30, 2010Publication date: February 10, 2011Applicant: University of Central Florida Research Foundation, Inc.Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajyoti Deb
-
Publication number: 20110033914Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.Type: ApplicationFiled: August 30, 2010Publication date: February 10, 2011Applicant: University of Central Florida Research Foundation, Inc.Inventors: Pappachan Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajyoti Deb
-
Publication number: 20100021453Abstract: Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the implementation or manipulation of triacylglycerol synthase like polypeptides or polynucleotides encoding the same. The methods are useful in identifying agents active against TB infection.Type: ApplicationFiled: August 24, 2009Publication date: January 28, 2010Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Vinod S. Dubey, Jaiyanth Daniel
-
Publication number: 20090023596Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.Type: ApplicationFiled: April 22, 2008Publication date: January 22, 2009Inventors: Pappachan Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajyoti Deb
-
Publication number: 20080014206Abstract: Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the implementation or manipulation of triacylglycerol synthase like polypeptides or polynucleotides encoding the same. The methods are useful in identifying agents active against TB infection.Type: ApplicationFiled: November 20, 2006Publication date: January 17, 2008Inventors: Pappachan Kolattukudy, Tatiana Sirakova, Vinod Dubey
-
Patent number: 6562349Abstract: It has been discovered that a vaccine comprised of fimbrin, a filamentous protein derived from the bacterial surface appendages of non-typable Haemophilus influenzae is useful in studying, preventing or reducing the severity of, otitis media. The gene sequence of the DNA coding for fimbrin and the amino acid sequence of fimbrin have also been determined. Vectors containing DNA coding for fimbrin have also been developed, and transformants have been prepared which contain such vectors and which express such DNA and provide a source of pure fimbrin.Type: GrantFiled: November 29, 1999Date of Patent: May 13, 2003Assignee: The Ohio State University Research FoundationInventors: Pappachan E. Kolattukudy, Lauren O. Bakaletz, Tatiana Sirakova
-
Patent number: 6030626Abstract: It has been discovered that a vaccine comprised of fimbrin, a filamentous protein derived from the bacterial surface appendages of non-typable Haemophilus influenzae is useful in studying, preventing or reducing the severity of, otitis media. The gene sequence of the DNA coding for fimbrin and the amino acid sequence of fimbrin have also been determined. Vectors containing DNA coding for fimbrin have also been developed, and transformants have been prepared which contain such vectors and which express such DNA and provide a source of pure fimbrin.Type: GrantFiled: June 6, 1995Date of Patent: February 29, 2000Assignee: Ohio State Research FoundationInventors: Pappachan E. Kolattukudy, Lauren O. Bakaletz, Tatiana Sirakova
-
Patent number: 5766608Abstract: It has been discovered that a vaccine comprised of fimbrin, a filamentous protein derived from the bacterial surface appendages of non-typable Haemophilus influenzae is useful in studying, preventing or reducing the severity of, otitis media. The gene sequence of the DNA coding for fimbrin and the amino acid sequence of fimbrin have also been determined. Vectors containing DNA coding for fimbrin have also been developed, and transformants have been prepared which contain such vectors and which express such DNA and provide a source of pure fimbrin.Type: GrantFiled: June 1, 1995Date of Patent: June 16, 1998Assignee: The Ohio State Research FoundationInventors: Pappachan E. Kolattukudy, Lauren O. Bakaletz, Tatiana Sirakova